These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35135140)

  • 1. Economic Evaluations of Next-Generation Precision Oncology: A Critical Review.
    Weymann D; Pataky R; Regier DA
    JCO Precis Oncol; 2018 Nov; 2():1-23. PubMed ID: 35135140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges.
    Weymann D; Dragojlovic N; Pollard S; Regier DA
    J Community Genet; 2022 Oct; 13(5):467-476. PubMed ID: 31273679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing in oncology: challenges in economic evaluations.
    Ehman M; Punian J; Weymann D; Regier DA
    Expert Rev Pharmacoecon Outcomes Res; 2024 Dec; 24(10):1115-1132. PubMed ID: 39096135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
    Heather EM; Payne K; Harrison M; Symmons DP
    Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions.
    Regier DA; Weymann D; Buchanan J; Marshall DA; Wordsworth S
    Value Health; 2018 Sep; 21(9):1043-1047. PubMed ID: 30224107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of next-generation sequencing to improve cancer management: A review of the clinical effectiveness and cost-effectiveness.
    Tan O; Shrestha R; Cunich M; Schofield DJ
    Clin Genet; 2018 Mar; 93(3):533-544. PubMed ID: 29265354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review.
    Mirza M; Goerke L; Anderson A; Wilsdon T
    Value Health; 2024 Sep; 27(9):1300-1309. PubMed ID: 38729563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children.
    Beale S; Sanderson D; Sanniti A; Dundar Y; Boland A
    Health Technol Assess; 2015 Jun; 19(46):1-90. PubMed ID: 26132578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of next-generation sequencing techniques in diagnosis of genetic disorders: A systematic review.
    Rezapour A; Souresrafil A; Barzegar M; Sheikhy-Chaman M; Tatarpour P
    Clin Genet; 2023 May; 103(5):513-528. PubMed ID: 36808726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and quality assessment of economic evaluation studies of injury prevention.
    Polinder S; Segui-Gomez M; Toet H; Belt E; Sethi D; Racioppi F; van Beeck EF
    Accid Anal Prev; 2012 Mar; 45():211-21. PubMed ID: 22269503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
    Seo MK; Cairns J
    BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.